T-cells and the Nobel Price
What does the Nobel Prize have to do with cancer research in Oslo Cancer Cluster? This year the Nobel Prize for Physiology and Medicine was awarded to James P. Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer. This was a breakthrough that has led to an entirely new class […]
Prestigious partnership for Vaccibody
Oslo Cancer Cluster member Vaccibody is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics. The aim of the collaboration is to explore positive effects from the combination of Vaccibody’s personalized cancer vaccine VB10.NEO and Nektar Therapeutics cancer drug NKTR-214. Pre-clinical results of the combination are very positive and the collaboration will […]
American tech and Norwegian health data
Combining country scale population data with world class computer systems and algorithms will push the boundaries of precision medicine. This is a story about the unique American-Norwegian collaboration that combines the best health data with the most powerful computers in a pioneer project run by Cancer Registry of Norway and Lawrence Livermore National Laboratory. Data to screen […]
Norwegian life science on exhibition
The strong life science actors in Norway joined forces during the conference Nordic Life Science Days 2018. Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway by being a significant partner for international clusters, global biopharma companies and academic centres. We used the conference Nordic Life Science Days 2018 in Stockholm this […]
The next wave in cancer immunotherapy
What is driving the next wave of innovation in cancer immunotherapy? This was the question the experts tried to answer in the oncology session of the conference Nordic Life Science Days in Stockholm 12 September. International experts from pharma, biotech, academia and the investment community discussed how different approaches to innovative cancer treatments could address […]
Ultimovacs acquires Immuneed
The Norwegian biotech company Ultimovacs acquires the immunotherapy technology business of the Swedish company Immuneed AB. The complementary technologies of the two companies provide a unique platform for development of novel vaccine solutions for treatment and possibly prevention of cancer. The acquired business has been named Ultimovacs AB and is now a fully-owned Swedish subsidiary […]
